Pulmonary Hypertension

Part of the series Contemporary Cardiology™ pp 321-336

Statins for Treatment of Pulmonary Hypertension

  • John L. Faul
  • , Peter N. Kao
  • , Toshihiko Nishimura
  • , Arthur Sung
  • , Hong Hu
  • , Ronald G. Pearl

* Final gross prices may vary according to local VAT.

Get Access


By virtue of their multiple actions, including anti-inflammatory, antiproliferative, and pro-apoptotic traits and the ability to restore endothelial vasoactive mediator production, statins have been proposed as potential therapies for pulmonary hypertension. In experimental studies in rats with pulmonary hypertension induced either by either monocrotaline or hypoxia, statins have blunted the severity of pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular remodeling, sometimes in association with the restoration of the endothelial cell production of nitric oxide. Pending trials that demonstrate the efficacy of statins in pulmonary arterial hypertension in humans, however, the clinical use of statins should be considered investigational.


statins pulmonary hypertension therapy monocrotaline chronic hypoxia experimental pulmonary hypertension simvastatin